Hexagon Capital Partners’s Zomedica Corp. ZOM Stock Holding History

Hexagon Capital Partners’s Portfolio ZOM Stock Details ZOM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-283	Closed	-$16	–	1831
2025 Q1	$16	Hold	283	–	–	﹤0.01%	1826
2024 Q4	$34	Hold	283	–	–	﹤0.01%	1825
2024 Q3	$39	Hold	283	–	–	﹤0.01%	1561
2024 Q2	$42	Hold	283	–	–	﹤0.01%	1438
2024 Q1	$41	Hold	283	–	–	﹤0.01%	1451
2023 Q4	$57	Hold	283	–	–	﹤0.01%	1397
2023 Q3	$47	Hold	283	–	–	﹤0.01%	1392
2023 Q2	$57	Hold	283	–	–	﹤0.01%	1400
2023 Q1	$60	Hold	283	–	–	﹤0.01%	1422
2022 Q4	$46	Buy	+283	New	+$58	﹤0.01%	1435

Other funds holding ZOM

Ancora Advisors Cleveland, Ohio $5.19B AUM 23.19% 1-Year Est. Return

Advisory Services Network Atlanta, Georgia $8.83B AUM 38.5% 1-Year Est. Return

Spire Wealth Management Mclean, Virginia $3.31B AUM 38.78% 1-Year Est. Return

Cary Street Partners Richmond, Virginia $4.58B AUM 24% 1-Year Est. Return

CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Pandora Wealth Oakbrook Terrace, Illinois $165M AUM 18.5% 1-Year Est. Return

Bogart Wealth LLC Mclean, Virginia $2.92B AUM 23.85% 1-Year Est. Return

Rossby Financial Melbourne, Florida $547M AUM 30.65% 1-Year Est. Return

Hexagon Capital Partners's ZOM Position: Q2 2025 in Review

Hexagon Capital Partners sold out of Zomedica Corp. (ZOM) in Q2 2025, closing a stake of 283 shares — an estimated $16 sold.

Hexagon Capital Partners first reported a position in ZOM in Q4 2022 and held it in 10 quarters. The position peaked at $60 in Q1 2023. 10 funds tracked by Wall St. Rank hold ZOM as of Q2 2025.

Hexagon Capital Partners reported no remaining Zomedica Corp. position as of Q2 2025 after selling out during the quarter.
Hexagon Capital Partners sold 283 Zomedica Corp. shares in Q2 2025, an estimated $16.
Hexagon Capital Partners first reported a position in Zomedica Corp. in Q4 2022 and held it in 10 quarters.
Hexagon Capital Partners's Zomedica Corp. position peaked at $60 in Q1 2023.
10 funds tracked by Wall St. Rank held Zomedica Corp. as of Q2 2025.

Based on Hexagon Capital Partners's 13F filing for Q2 2025, filed 11 Aug 2025.